Surfactant therapy using a bronchofiberscope in respiratory distress syndrome

• Published in: Pediatrics international Vol. 65; no. 1; pp. e15478 - n/a
• Main Authors: Wasa, Masanori, Hasegawa, Hisaya, Kihara, Hirotaka, Yamada, Yosuke, Mizogami, Masae, Kitamura, Rei, Ikeda, Kenta
• Format: Journal Article
• Language: English
• Published: Australia Blackwell Publishing Ltd 01.01.2023
• Subjects: Adverse events; Birth weight; bronchofiberscope; Comorbidity; Continuous Positive Airway Pressure; Feasibility studies; Gestational age; Humans; Infant; Infant, Newborn; Infant, Premature; Infants; Intubation; Lipoproteins; Mechanical ventilation; Pediatrics; Pilot Projects; preterm infant; Pulmonary Surfactants - therapeutic use; Respiratory distress syndrome; Respiratory Distress Syndrome, Newborn - diagnosis; Respiratory Distress Syndrome, Newborn - drug therapy; Surface-Active Agents - therapeutic use; surfactant; Surfactants; respiratory distress syndrome; preterm infant; surfactant; bronchofiberscope
• ISSN: 1328-8067; 1442-200X
• DOI: 10.1111/ped.15478

Background Avoiding endotracheal intubation and using nasal continuous positive airway pressure as the initial treatment is recommended in infants with respiratory distress syndrome (RDS), and modes of lesser invasive surfactant administration have recently been reported. We report a pilot study assessing the feasibility of surfactant therapy using a bronchofiberscope (STUB) in RDS. Methods Surfactant was administered to 31 preterm infants (gestational age range of 28 weeks 0 days to 36 weeks 6 days) diagnosed with RDS, through the working channel of the bronchofiberscope or endotracheal tubes. Patient characteristics, outcomes, adverse events, and comorbidities were assessed in the two groups. Results Twelve infants received STUB. Two of the 12 infants (17%) needed subsequent intubation and additional surfactant administration. Nineteen infants received surfactant through endotracheal tubes. Four of the 19 infants (21%) required additional surfactants. There was no significant difference in the number of infants that needed additional surfactant (p = 1.00). Gestational age, birthweight, length of hospitalization, adverse events, such as desaturations and bradycardias, and comorbidities were similar between the two groups. Days of invasive ventilation were significantly shorter in the STUB group (p = 0.0002). Conclusion STUB was feasible in this small cohort and reduced the need for intubation to 17%, leading to fewer days of invasive ventilation, without increasing comorbidities and adverse events. To the best of our knowledge, this is the first study to administer surfactants using bronchofiberscopes.